Ganirelix acetate is a synthetic gonadotropin-releasing hormone (GnRH) antagonist used to prevent premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation for assisted reproductive technologies, such as in vitro fertilization (IVF) [1]. It is administered via subcutaneous injection [1].
How does Ganirelix acetate prevent LH surges?
Ganirelix acetate works by competitively binding to GnRH receptors in the pituitary gland. This binding prevents endogenous GnRH from stimulating the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). By blocking the LH surge, Ganirelix acetate helps ensure that egg maturation occurs in a controlled manner, optimizing the chances of successful egg retrieval and subsequent fertilization [1].
When does Ganirelix acetate treatment typically begin?
Treatment with Ganirelix acetate usually starts on the morning of the sixth day of stimulation with gonadotropins. Dosing continues daily until the day of human chorionic gonadotropin (hCG) administration [1].
What are the reported side effects of Ganirelix acetate?
Common side effects associated with Ganirelix acetate include nausea, headache, and local injection site reactions such as redness, itching, or swelling [1]. Less common but more serious side effects can include ovarian hyperstimulation syndrome (OHSS), allergic reactions, and potential risks during pregnancy, although these are typically related to the IVF procedure itself rather than the GnRH antagonist [1].
Are there alternatives to Ganirelix acetate for preventing LH surges?
Another class of GnRH modulators, GnRH agonists, can also be used to prevent premature LH surges. However, GnRH agonists typically involve a different administration schedule and mechanism, often leading to an initial flare-up of hormone release before suppressing it, which can influence the stimulation protocol and response [2]. Other GnRH antagonists are also available.
What is the patent status of Ganirelix acetate?
Information regarding the patent status and exclusivity periods for Ganirelix acetate can be found on specialized databases. For instance, DrugPatentWatch.com tracks patent expirations and market exclusivity for pharmaceutical products, which can indicate when generic versions might become available [3].
Who manufactures Ganirelix acetate?
Ganirelix acetate is manufactured by several pharmaceutical companies. The brand name formulation, typically marketed as Antagon, was originally developed by Organon, which is now part of Merck & Co. [4]. Generic versions are also produced by other pharmaceutical manufacturers.